Polypill is a fixed-dose combination that contains three or more active ingredients used as a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects.A novel and a...Polypill is a fixed-dose combination that contains three or more active ingredients used as a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects.A novel and accurate liquid chromatography tandem mass spectrometry method using electrospray ionization mode has been developed and validated for the simultaneous determination of amlodipine（AMD）,valsartan（VAL） using losartan（LOS） as an internal standard（IS）,and hydrochlorothiazide（HCT） using furosemide（FSD） as an IS.The separation was carried on Aquasil C18（50 mm×2.1 mm,5μm） reversed phase column using acetonitrile and water containing 0.1%formic acid（50：50,v/v） as the mobile phase.The method was validated in terms of linearity,accuracy and precision over the concentration range of 1-1000 ng/mL.The intra and inter-day precision and accuracy,stability and extraction recoveries of all the analytes were in the acceptable range.This method can be successfully applied to the pharmacokinetic study of AMD,VAL and HCT when given as a polypill.展开更多
A sensitive and selective method has been proposed for the simultaneous determination of amlodipine(AML),valsartan(VAL) and hydrochlorothiazide(HCTZ) in human plasma by liquid chromatography–tandem mass spectrometry...A sensitive and selective method has been proposed for the simultaneous determination of amlodipine(AML),valsartan(VAL) and hydrochlorothiazide(HCTZ) in human plasma by liquid chromatography–tandem mass spectrometry(LC–MS/MS). The analytes and their deuterated analogs were quantitatively extracted from100 μL human plasma by solid phase extraction on Oasis HLB cartridges. The chromatographic separation of the analytes was achieved on a Chromolith RP18 e(100 mm × 4.6 mm) analytical column within 2.5 min. The resolution factor between AML and VAL, AML and HCTZ, and VAL and HCTZ was 2.9, 1.5 and 1.4, respectively,under isocratic conditions. The method was validated over a dynamic concentration range of 0.02–20.0 ng/m L for AML, 5.00–10,000 ng/m L for VAL and 0.20–200 ng/m L for HCTZ. Ion-suppression/enhancement effects were investigated by post-column infusion technique. The mean IS-normalized matrix factors for AML, VAL and HCTZ were 0.992, 0.994 and 0.998, respectively. The intra-batch and inter-batch precision(% CV) across quality control levels was ≤ 5.56% and the recovery was in the range of 93.4%–99.6% for all the analytes. The method was successfully applied to a bioequivalence study of 5 mg AML + 160 mg VAL + 12.5 mg HCTZ tablet formulation(test and reference) in 18 healthy Indian males under fasting. The mean log-transformed ratios of C max, AUC0–120 h and AUC0-inf and their 90% CIs were within 90.2%–102.1%. The assay reproducibility was demonstrated by reanalysis of 90 incurred samples.展开更多
Amlodipine/valsartan(Aml/Val)single-pill combination(SPC)therapy has been widely used and studied in clinical practice in recent years.This article reviews the Chinese and English literature on the clinical use of Aml...Amlodipine/valsartan(Aml/Val)single-pill combination(SPC)therapy has been widely used and studied in clinical practice in recent years.This article reviews the Chinese and English literature on the clinical use of Aml/Val SPC therapy in Chinese hypertensive patients.According to five studies concerning the efficacy and safety of this treatment,Aml/Val SPC therapy was more efficacious than monotherapy with valsartan,amlodipine,or the nifedipine gastrointestinal therapeutic system.This treatment showed greater blood pressure-lowering effects,a higher blood pressure control rate,and a higher response rate.Aml/Val SPC treatment was well tolerated,with adverse event rates similar to those of monotherapy with valsartan or amlodipine and significantly rarer adverse events compared with the nifedipine gastrointestinal therapeutic system.Aml/Val SPC is a highly efficacious and well-tolerated antihypertensive treatment in Chinese hypertensive patients.展开更多
A simple, sensitive, and specific method was developed for simultaneous determination of Amlodipine besylate (AML), Valsartan (Vals) and Hydrochlorothiazide (HCT) by high performance liquid chromatography without prev...A simple, sensitive, and specific method was developed for simultaneous determination of Amlodipine besylate (AML), Valsartan (Vals) and Hydrochlorothiazide (HCT) by high performance liquid chromatography without previous separation. Satisfactory resolution was achieved using a RP-C18 chromatographic column, Phenomenex Kinetex (150 mm × 4.6 mm i.d) and a mobile phase consisting of acetonitrile-phosphate buffer (0.05 M) with pH 2.8 in the proportion of (40/60, v/v) at a flow rate 0.8 mL/min and the wavelength detection was 227 nm. The retention time for HCT, AML and VAls was 2.26, 3.16 and 11.19 min;respectively. The described method was linear over a range of 4-28 μg /ml, 5-40 μg /ml and 1-12 μg /ml for AML, Vals and HCT;respectively. The mean percent recoveries were 99.94%, 99.96% and 99.78% for AML, Vals and HCT;respectively. F-test and t-test at 95%con?dence level were used to check the intermediate precision data obtained under different experimental setups. The method could be used for analysis of combined dose tablet formulation containing AML, Vals, HCT as well as spiked human plasma.展开更多
New HPLC method was developed for determination of amlodipine and valsartan in their binary mixture as a part of routine control of combined formulations. The method was validated to meet official requirements includi...New HPLC method was developed for determination of amlodipine and valsartan in their binary mixture as a part of routine control of combined formulations. The method was validated to meet official requirements including selectivity, stability, linearity, precision and accuracy. Chromatography was carried out using a LiChrospher RP-18 column, a mixture containing acetonitrile, phosphate buffer of pH 3.5 and methanol (45:45:10, v/v/v) and new fluorescence detection at 255 nm for excitation and 448 nm for emission. The effect of methanol content, pH of the buffer, flow rate, detection wavelengths and column temperature was estimated in robustness study, according to a plan defined by the Plackett-Burman design. For identification of significant effects, both graphical and statistical methods were used. Ro-bustness for dissolution test was checked estimating the effects of paddle speed, temperature and pH of dissolution medium. The method was proved to complying with all official guidelines. Therefore, it is suitable for determination of amlodipine and valsartan in their binary mixtures for different analytical and pharmaceutical purposes.展开更多
A simple,rapid,accurate,precise and robust HPLC method was developed for the simultaneous determination of fimasartan and amlodipine in tablet dosage form.Furthermore,stability of active ingredients was evaluated unde...A simple,rapid,accurate,precise and robust HPLC method was developed for the simultaneous determination of fimasartan and amlodipine in tablet dosage form.Furthermore,stability of active ingredients was evaluated under normal and stress conditions.The isocratic elution was accomplished by Nucleosil C18 column(250 mm×4.6 mm,5 mm)at 40℃.The mobile phase consisted of acetonitrile and 0.02 M monopotassium phosphate buffer(pH 2.2)in the ratio of 50:50(v/v)was eluted at 1.0 ml/min.The eluent was monitored by the UV detector for fimasartan and amlodipine at 237 nm for 8 min,detection time.The validation of HPLC method was carried out in accordance with the ICH guidelines.展开更多
The purpose of this research was to evaluate the effect of starch- and xanthan gum-based food thickeners on the bitterness and dissolution of amlodipine besilate (AMPB) loaded orally disintegrating tablets (ODT) for p...The purpose of this research was to evaluate the effect of starch- and xanthan gum-based food thickeners on the bitterness and dissolution of amlodipine besilate (AMPB) loaded orally disintegrating tablets (ODT) for potential use with patients with dysphagia. A conventional dissolution test simulating the oral cavity was performed and the taste sensor output of the dissolved sample was evaluated over a 60-seconds period. When four types of AMPB loaded ODTs were tested alone, at 60 seconds, branded product (A) was the least bitter, followed by generic product (B)/generic product (C) which were equal, and finally generic product (D) which was the most bitter. Inhibition of bitterness of AMPB loaded ODTs mixed thickeners, 1.0 (w/v) % xanthan gum-based food thickener solution was significantly strong. The 7.1 (w/v) % and 4.7 (w/v) % starch-based food thickeners solution also effective in bitterness inhibition compared to the 2.4 (w/v) % starch-based food thickener solution. The dissolution test under pH 1.2 in related to 7.1 (w/v) % and 4.7 (w/v) % starch-based thickener contained each of AMPB loaded ODTs were associated with an almost complete amlodipine (AMP) dissolution (almost 90% at 10 minutes), whereas the 1.0, 2.0, 3.0 (w/v) % xanthan gum-based food thickener solution containing AMPB loaded ODTs did not show complete AMP dissolution and there were large variations in the initial dissolution stage. This suggests that a mixture of xanthan gum-based thickener and AMPB loaded ODT poses a risk of reduction of bioavailability. In conclusion, a mixture of 4.7 (w/v) % or 7.1 (w/v) % starch-based thickener with ODTs provides complete release of AMP and superior bitterness inhibition, so is the best choice for administration to patients with dysphagia.展开更多
Objective:To systematically evaluate the efficacy and safety of Nephritis Rehabilitation Tablet(NRT)combined with valsartan in treatment of chronic glomerulonephritis(CGN).Methods:Computer search databases such as CNK...Objective:To systematically evaluate the efficacy and safety of Nephritis Rehabilitation Tablet(NRT)combined with valsartan in treatment of chronic glomerulonephritis(CGN).Methods:Computer search databases such as CNKI,CBM,VIP,wanfang,Embase,PubMed and Cochrane library,and find all randomized controlled trials(RCTs)comparing NRT combined with valsartan versus valsartan in treatment of chronic glomerulonephritis.The search time limit is to build the database until October 2020.RCTs were screened according to the inclusion and exclusion criteria.After data extraction and quality assessment,the Cochrane risk of bias tool was used to evaluate the methodological quality of these studies.Meta-analysis was performed by Review Manager 5.2,and GRADE system for evidence quality evaluation.Results:We have identified a total of 24 eligible RCTs with 2082 participants and completed a meta-analysis based on these RCTs.The results of the meta-analysis showed that compared with valsartan,NRT combined with valsartan treatment showed effective curative effect in terms of effective treatment rate(OR=4.72;95%CI,3.67,6.08;P<0.00001),24h urine protein quantification(MD=-0.52;95%CI,-0.59,-0.44;P<0.00001),serum creatinine(Scr)(MD=-10.33;95%CI,-14.00,-6.66;P<0.00001),Systolic blood pressure(SBP)(MD=-11.42;95%CI,-17.67,-5.17;P=0.0003),Diastolic blood pressure(DBP)(MD=-6.28;95%CI,-9.14,-3.42;P<0.0001),Blood urine nitrogen(BUN)(MD=-0.02;95%CI,-0.41,0.37;P=0.93),plasma albumin(ALB)(MD=5.05;95%CI,4.27,5.84;P<0.00001),and adverse reactions(OR=0.93,95%CI,0.54,1.60;P=0.78).No serious adverse events were mentioned in these studies.And based on the results of the systematic review,the GRADE system recommended ranking method was used to evaluate the quality of evidence and the recommendation level.The results showed that the level of evidence was moderate and the recommendation intensity was weak recommendation.Conclusions:NRT combined with valsartan has a significant effect on the treatment of CGN,and the treatment effect is better than valsartan alone.There are no obvious adverse reactions during the treatment process.However,due to the generally low quality of the literature included in these studies,and the variability of the evaluation methods of each study,morelarge samples,multi-center,high-quality samples are still needed RCTs are further verified.展开更多
文摘Polypill is a fixed-dose combination that contains three or more active ingredients used as a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects.A novel and accurate liquid chromatography tandem mass spectrometry method using electrospray ionization mode has been developed and validated for the simultaneous determination of amlodipine（AMD）,valsartan（VAL） using losartan（LOS） as an internal standard（IS）,and hydrochlorothiazide（HCT） using furosemide（FSD） as an IS.The separation was carried on Aquasil C18（50 mm×2.1 mm,5μm） reversed phase column using acetonitrile and water containing 0.1%formic acid（50：50,v/v） as the mobile phase.The method was validated in terms of linearity,accuracy and precision over the concentration range of 1-1000 ng/mL.The intra and inter-day precision and accuracy,stability and extraction recoveries of all the analytes were in the acceptable range.This method can be successfully applied to the pharmacokinetic study of AMD,VAL and HCT when given as a polypill.
文摘A sensitive and selective method has been proposed for the simultaneous determination of amlodipine(AML),valsartan(VAL) and hydrochlorothiazide(HCTZ) in human plasma by liquid chromatography–tandem mass spectrometry(LC–MS/MS). The analytes and their deuterated analogs were quantitatively extracted from100 μL human plasma by solid phase extraction on Oasis HLB cartridges. The chromatographic separation of the analytes was achieved on a Chromolith RP18 e(100 mm × 4.6 mm) analytical column within 2.5 min. The resolution factor between AML and VAL, AML and HCTZ, and VAL and HCTZ was 2.9, 1.5 and 1.4, respectively,under isocratic conditions. The method was validated over a dynamic concentration range of 0.02–20.0 ng/m L for AML, 5.00–10,000 ng/m L for VAL and 0.20–200 ng/m L for HCTZ. Ion-suppression/enhancement effects were investigated by post-column infusion technique. The mean IS-normalized matrix factors for AML, VAL and HCTZ were 0.992, 0.994 and 0.998, respectively. The intra-batch and inter-batch precision(% CV) across quality control levels was ≤ 5.56% and the recovery was in the range of 93.4%–99.6% for all the analytes. The method was successfully applied to a bioequivalence study of 5 mg AML + 160 mg VAL + 12.5 mg HCTZ tablet formulation(test and reference) in 18 healthy Indian males under fasting. The mean log-transformed ratios of C max, AUC0–120 h and AUC0-inf and their 90% CIs were within 90.2%–102.1%. The assay reproducibility was demonstrated by reanalysis of 90 incurred samples.
文摘Amlodipine/valsartan(Aml/Val)single-pill combination(SPC)therapy has been widely used and studied in clinical practice in recent years.This article reviews the Chinese and English literature on the clinical use of Aml/Val SPC therapy in Chinese hypertensive patients.According to five studies concerning the efficacy and safety of this treatment,Aml/Val SPC therapy was more efficacious than monotherapy with valsartan,amlodipine,or the nifedipine gastrointestinal therapeutic system.This treatment showed greater blood pressure-lowering effects,a higher blood pressure control rate,and a higher response rate.Aml/Val SPC treatment was well tolerated,with adverse event rates similar to those of monotherapy with valsartan or amlodipine and significantly rarer adverse events compared with the nifedipine gastrointestinal therapeutic system.Aml/Val SPC is a highly efficacious and well-tolerated antihypertensive treatment in Chinese hypertensive patients.
文摘A simple, sensitive, and specific method was developed for simultaneous determination of Amlodipine besylate (AML), Valsartan (Vals) and Hydrochlorothiazide (HCT) by high performance liquid chromatography without previous separation. Satisfactory resolution was achieved using a RP-C18 chromatographic column, Phenomenex Kinetex (150 mm × 4.6 mm i.d) and a mobile phase consisting of acetonitrile-phosphate buffer (0.05 M) with pH 2.8 in the proportion of (40/60, v/v) at a flow rate 0.8 mL/min and the wavelength detection was 227 nm. The retention time for HCT, AML and VAls was 2.26, 3.16 and 11.19 min;respectively. The described method was linear over a range of 4-28 μg /ml, 5-40 μg /ml and 1-12 μg /ml for AML, Vals and HCT;respectively. The mean percent recoveries were 99.94%, 99.96% and 99.78% for AML, Vals and HCT;respectively. F-test and t-test at 95%con?dence level were used to check the intermediate precision data obtained under different experimental setups. The method could be used for analysis of combined dose tablet formulation containing AML, Vals, HCT as well as spiked human plasma.
文摘New HPLC method was developed for determination of amlodipine and valsartan in their binary mixture as a part of routine control of combined formulations. The method was validated to meet official requirements including selectivity, stability, linearity, precision and accuracy. Chromatography was carried out using a LiChrospher RP-18 column, a mixture containing acetonitrile, phosphate buffer of pH 3.5 and methanol (45:45:10, v/v/v) and new fluorescence detection at 255 nm for excitation and 448 nm for emission. The effect of methanol content, pH of the buffer, flow rate, detection wavelengths and column temperature was estimated in robustness study, according to a plan defined by the Plackett-Burman design. For identification of significant effects, both graphical and statistical methods were used. Ro-bustness for dissolution test was checked estimating the effects of paddle speed, temperature and pH of dissolution medium. The method was proved to complying with all official guidelines. Therefore, it is suitable for determination of amlodipine and valsartan in their binary mixtures for different analytical and pharmaceutical purposes.
基金This work was supported by a grant from the Korean Health Technology R&D Project,Ministry for Health,Welfare and Family Affairs,Republic of Korea(A092018)a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation(HT13C0011)in South Korea.
文摘A simple,rapid,accurate,precise and robust HPLC method was developed for the simultaneous determination of fimasartan and amlodipine in tablet dosage form.Furthermore,stability of active ingredients was evaluated under normal and stress conditions.The isocratic elution was accomplished by Nucleosil C18 column(250 mm×4.6 mm,5 mm)at 40℃.The mobile phase consisted of acetonitrile and 0.02 M monopotassium phosphate buffer(pH 2.2)in the ratio of 50:50(v/v)was eluted at 1.0 ml/min.The eluent was monitored by the UV detector for fimasartan and amlodipine at 237 nm for 8 min,detection time.The validation of HPLC method was carried out in accordance with the ICH guidelines.
文摘The purpose of this research was to evaluate the effect of starch- and xanthan gum-based food thickeners on the bitterness and dissolution of amlodipine besilate (AMPB) loaded orally disintegrating tablets (ODT) for potential use with patients with dysphagia. A conventional dissolution test simulating the oral cavity was performed and the taste sensor output of the dissolved sample was evaluated over a 60-seconds period. When four types of AMPB loaded ODTs were tested alone, at 60 seconds, branded product (A) was the least bitter, followed by generic product (B)/generic product (C) which were equal, and finally generic product (D) which was the most bitter. Inhibition of bitterness of AMPB loaded ODTs mixed thickeners, 1.0 (w/v) % xanthan gum-based food thickener solution was significantly strong. The 7.1 (w/v) % and 4.7 (w/v) % starch-based food thickeners solution also effective in bitterness inhibition compared to the 2.4 (w/v) % starch-based food thickener solution. The dissolution test under pH 1.2 in related to 7.1 (w/v) % and 4.7 (w/v) % starch-based thickener contained each of AMPB loaded ODTs were associated with an almost complete amlodipine (AMP) dissolution (almost 90% at 10 minutes), whereas the 1.0, 2.0, 3.0 (w/v) % xanthan gum-based food thickener solution containing AMPB loaded ODTs did not show complete AMP dissolution and there were large variations in the initial dissolution stage. This suggests that a mixture of xanthan gum-based thickener and AMPB loaded ODT poses a risk of reduction of bioavailability. In conclusion, a mixture of 4.7 (w/v) % or 7.1 (w/v) % starch-based thickener with ODTs provides complete release of AMP and superior bitterness inhibition, so is the best choice for administration to patients with dysphagia.
基金The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine(No.2020XKTD-A04)Disciplinary Innovation Team Plan of Shaanxi University of Traditional Chinese Medicine(No.2019-QN02)。
文摘Objective:To systematically evaluate the efficacy and safety of Nephritis Rehabilitation Tablet(NRT)combined with valsartan in treatment of chronic glomerulonephritis(CGN).Methods:Computer search databases such as CNKI,CBM,VIP,wanfang,Embase,PubMed and Cochrane library,and find all randomized controlled trials(RCTs)comparing NRT combined with valsartan versus valsartan in treatment of chronic glomerulonephritis.The search time limit is to build the database until October 2020.RCTs were screened according to the inclusion and exclusion criteria.After data extraction and quality assessment,the Cochrane risk of bias tool was used to evaluate the methodological quality of these studies.Meta-analysis was performed by Review Manager 5.2,and GRADE system for evidence quality evaluation.Results:We have identified a total of 24 eligible RCTs with 2082 participants and completed a meta-analysis based on these RCTs.The results of the meta-analysis showed that compared with valsartan,NRT combined with valsartan treatment showed effective curative effect in terms of effective treatment rate(OR=4.72;95%CI,3.67,6.08;P<0.00001),24h urine protein quantification(MD=-0.52;95%CI,-0.59,-0.44;P<0.00001),serum creatinine(Scr)(MD=-10.33;95%CI,-14.00,-6.66;P<0.00001),Systolic blood pressure(SBP)(MD=-11.42;95%CI,-17.67,-5.17;P=0.0003),Diastolic blood pressure(DBP)(MD=-6.28;95%CI,-9.14,-3.42;P<0.0001),Blood urine nitrogen(BUN)(MD=-0.02;95%CI,-0.41,0.37;P=0.93),plasma albumin(ALB)(MD=5.05;95%CI,4.27,5.84;P<0.00001),and adverse reactions(OR=0.93,95%CI,0.54,1.60;P=0.78).No serious adverse events were mentioned in these studies.And based on the results of the systematic review,the GRADE system recommended ranking method was used to evaluate the quality of evidence and the recommendation level.The results showed that the level of evidence was moderate and the recommendation intensity was weak recommendation.Conclusions:NRT combined with valsartan has a significant effect on the treatment of CGN,and the treatment effect is better than valsartan alone.There are no obvious adverse reactions during the treatment process.However,due to the generally low quality of the literature included in these studies,and the variability of the evaluation methods of each study,morelarge samples,multi-center,high-quality samples are still needed RCTs are further verified.
